Clinical trials: Dry Skin
Asthma
A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250/50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With Asthma
This is a multi-centre, randomised, double-blind, double-dummy, two way cross-over, 12 week non inferiority study to evaluate the efficacy, safety, and tolerability of FSC 250/50 mcg capsule-based inhaler and FSC 250/50 mcg…
- Trial name
- NCT01978119
- Testing
- FSC
- Where
- 13 sites in Russia, Ukraine
- Volunteers
- 124 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)
Studies to date provides substantial evidence for the effectiveness for UMEC 62.5 microgram (mcg) as a long term maintenance therapy for the treatment of COPD; this study further evaluates the efficacy and safety of UMEC 62.5 mcg…
- Trial name
- NCT02184611
- Testing
- Umeclidinium bromide
- Where
- 26 sites in China, South Korea
- Volunteers
- 308 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Cetaphil Restoraderm Effect on Young Children With Atopic Dermatitis
The purpose of this study is to evaluate the effect of Cetaphil® Restoraderm® skin restoring moisturizer in reducing the signs and symptoms of very dry atopic skin in young children.
- Trial name
- NCT02589392
- Testing
- Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash, Cetaphil® Restoraderm® body wash
- Where
- 8 sites in China, Philippines
- Volunteers
- 120 people
- Sponsor
- Galderma R&D
Xerostomia
Effects of an External Oral Irrigation Device on Patients With Dry Mouth
The purpose of this research study is to test the effectiveness of treating dry mouth through water rehydration using this extra oral water pump/irrigation device.
- Trial name
- NCT04901507
- Testing
- The Voutia System
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Virginia Commonwealth University
Dry Eye
A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes
The objective of this study was to compare the safety and efficacy of 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- VELOS-2 (NCT03846453)
- Testing
- HL036 Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 637 people
- Sponsor
- HanAll BioPharma Co., Ltd.
Xerostomia, Sjogren Syndrome
Green Tea Lozenges for the Management of Dry Mouth
The goal of this proposal is to investigate the effectiveness of a Medical College of Georgia patent pending formulation of natural plant extracts on patients with xerostomia.
- Conditions
- Xerostomia, Sjogren Syndrome, Dry Mouth
- Trial name
- NCT01647737
- Testing
- MighTeaFlow, Xylitol
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Augusta University
Dry Eye Syndromes
A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.
A prospective, randomized, placebo and active comparator controlled study of CP-690,550 in subjects with dry eye.
- Trial name
- NCT00784719
- Testing
- CP-690,550, Cyclosporine, CP-690,550 Vehicle
- Where
- 27 sites in United States
- Volunteers
- 327 people
- Sponsor
- Pfizer
Dysphagia, Pain
Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer
This randomized pilot clinical trial studies dexamethasone in reducing oral pain and dry mouth after surgery in patients with oropharyngeal cancer. Dexamethasone may help lower pain and dry mouth caused by surgery.
- Conditions
- Dysphagia, Pain, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT01748942
- Testing
- Dexamethasone, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- OHSU Knight Cancer Institute
Chronic Obstructive Pulmonary Disease
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects
AZD8871 is a new chemical entity possessing long-acting effect in a single molecule which presents a novel treatment approach to chronic obstructive pulmonary disease [COPD] and potentially also asthma (in combination with an…
- Trial name
- NCT02814656
- Testing
- AZD8871
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Dry Eye Syndromes, Meibomian Gland Dysfunction
Mechanisms of Light-based Therapies for Dry Eye Disease
Dry eye disease is a common condition affecting millions worldwide and costing millions in healthcare due to reduced work productivity and quality of life.
- Trial name
- MOLT (NCT06004895)
- Testing
- Actual IPL, LLLT
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- Aston University
Dry Eye, Meibomian Gland Dysfunction
TearCare System to Treat Dry Eye Disease
In this study, the TearCare System will be compared with the LipiFlow Thermal Pulsation System in patients with dry eye disease.
- Trial name
- OLYMPIA (NCT03857919)
- Testing
- TearCare, LipiFlow
- Where
- 10 sites in United States
- Volunteers
- 235 people
- Sponsor
- Sight Sciences, Inc.
Dry Eye
Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)
The objective of this study is to compare the safety and efficacy of YP-P10 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT05467293
- Testing
- 0.3% YP-P10 Ophthalmic Solution, 1% YP-P10 Ophthalmic Solution
- Where
- 7 sites in United States
- Volunteers
- 257 people
- Sponsor
- Yuyu Pharma, Inc.
Dry Eye Syndrome
The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability
The purpose of this study is to investigate how the addition of a new emulsion artificial tear to the tear layer of dry eye and normal patients affects aberrometry, contrast sensitivity, and reading ability over time.
- Trial name
- NCT01013077
- Testing
- Optive, Soothe, New Emulsion, Soothe, New Emulsion, Optive, New Emulsion, Optive, Soothe
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Southern California College of Optometry at Marshall B. Ketchum University
Dry Eye Syndromes
Pilot Study of TearCare System - Long-Term Extension
The objective of the study is to evaluate the long-term clinical utility, safety, and effectiveness of re-treatment with the TearCare™ System in adult patients with dry eye syndrome who had previously been treated with the…
- Trial name
- NCT03804502
- Testing
- TearCare
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sight Sciences, Inc.
Dry Eye Syndrome
Safety and Tolerability of Artificial Tears in Dry Eye Subjects
The safety and tolerability of two new artificial tears will be compared to a currently-available artificial tear in subjects with dry eye. Each subject will receive all three products in a randomly assigned order.
- Trial name
- NCT00932477
- Testing
- Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Glycerin and Polysorbate 80 based artificial tear
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Allergan
Dry Eye, Sjogren Syndrome
Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye
Dry eye is a chronic condition that decreases function and affect visual function with severe discapacity until now treatments are based in artificial eye drops.
- Trial name
- NCT02257957
- Testing
- PRP injection, Standard care Hyaluronic acid eye drops
- Volunteers
- 30 people
- Sponsor
- Universidad Nacional de Colombia
Dry Eye
A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease
A Multi-Center, Phase 2, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% Novel Formulation) Compared to Vehicle in Subjects…
- Trial name
- NCT03916042
- Testing
- Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Sjögren Syndrome
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome (SjS).
- Trial name
- TWINSS (NCT03905525)
- Testing
- CFZ533
- Where
- 71 sites in United States, Argentina and 21 more
- Volunteers
- 273 people
- Sponsor
- Novartis Pharmaceuticals
Sjogren's Syndrome
Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
This study will evaluate the safety and tolerability of iscalimab at two dose levels in patients with Sjögren's Syndrome, who participated in the TWINSS core study, CCFZ533B2201 (NCT03905525).
- Trial name
- TWINSS Extn (NCT04541589)
- Testing
- Iscalimab
- Where
- 62 sites in United States, Argentina and 21 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Maculopathy, Age-Related Maculopathies
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
The purpose of this study is to determine the safety and tolerability of multiple doses of RN6G in subjects with advanced dry, age-related macular degeneration including geographic atrophy.
- Conditions
- Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration
- Trial name
- NCT01003691
- Testing
- RN6G
- Where
- 24 sites in United States
- Volunteers
- 24 people
- Sponsor
- Pfizer